RT Journal Article
SR Electronic
T1 Predicting the epidemic trend of COVID-19 in China and across the world using the machine learning approach
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.18.20038117
DO 10.1101/2020.03.18.20038117
A1 Li, Mengyuan
A1 Zhang, Zhilan
A1 Jiang, Shanmei
A1 Liu, Qian
A1 Chen, Canping
A1 Zhang, Yue
A1 Wang, Xiaosheng
YR 2020
UL http://medrxiv.org/content/early/2020/04/20/2020.03.18.20038117.abstract
AB Background Although COVID-19 has been well controlled in China, it is rapidly spreading outside the country and may have catastrophic results globally without implementation of necessary mitigation measures. Because the COVID-19 outbreak has made comprehensive and profound impacts on the world, an accurate prediction of its epidemic trend is significant. Although many studies have predicted the COVID-19 epidemic trend, most have used early-stage data and focused on Chinese cases.Methods We first built models to predict daily numbers of cumulative confirmed cases (CCCs), new cases (NCs), and death cases (DCs) of COVID-19 in China based on data from January 20, 2020, to March 1, 2020. Based on these models, we built models to predict the epidemic trend across the world (outside China). We also built models to predict the epidemic trend in Italy, Spain, Germany, France, UK, and USA where COVID-19 is rapidly spreading.Results The COVID-19 outbreak will have peaked on February 22, 2020, in China and will peak on May 22, 2020, across the world. It will be basically under control in early April 2020 in China and late August 2020 across the world. The total number of COVID-19 cases will reach around 89,000 in China and 6,126,000 across the world during the epidemic. Around 4,000 and 290,000 people will die of COVID-19 in China and across the world, respectively. The COVID-19 outbreak will have peaked recently in Italy and will peak in Spain, Germany, France, UK, and USA within two weeks.Conclusion The COVID-19 outbreak is controllable in the foreseeable future if comprehensive and stringent control measures are taken.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the China Pharmaceutical University (grant numbers 3150120001 to XW).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe downloaded the statistics of confirmed COVID-19 cases in China from the National Health Committee of China (http://www.nhc.gov.cn/), including the daily numbers of CCCs, NCs, and DCs since January 20, 2020. The data for the statistics of confirmed COVID-19 cases outside China were downloaded from Worldometer (https://www.worldometers.info/coronavirus/#countries). CCCscumulative confirmed casesNCsnew casesDCsdeath casesCOVID-19the corona virus disease 2019SARS-CoV-2the 2019 novel coronavirusK-S testKolmogorov-Smirnov test.